Patient and disease characteristics
| Characteristic . | Value . |
|---|---|
| No. of patients | 170 |
| Age range, y (median) | 12.1-78.9 (51.5) |
| Sex, male/female, no. (%) of patients | 93 (55)/77 (45) |
| Months from diagnosis to HCT, range (median) | 2-314 (15) |
| HCT-CI, no. (%) | 114 |
| 0 | 40 (35) |
| 1 | 19 (17) |
| 2 | 21 (19) |
| 3 | 14 (12) |
| 4 | 10 (9) |
| 5 | 5 (4) |
| 6 | 5 (4) |
| Type of myelofibrosis, no. (%) | |
| Primary | 101 (59) |
| Secondary | 69 (41) |
| Essential thrombocythemia | 46 (67) |
| Polycythemia vera | 22 (32) |
| Hairy cell leukemia | 1 (1) |
| Cytogenetic classification, no. (%) | |
| Favorable | 17 (10) |
| Normal | 88 (52) |
| Other | 37 (22) |
| Unfavorable | 25 (15) |
| Unknown | 3 (1) |
| JAK2 mutational status, no. (%) | |
| JAK2 wild-type | 51 (30) |
| JAK2-V617F mutant | 43 (25) |
| Not done | 76 (45) |
| Splenectomy, no. (%) | |
| No | 136 (80) |
| Yes | 31 (18) |
| Unknown* | 3 (2) |
| Grade of bone marrow fibrosis,20 no. (%) | |
| 1 | 13 (8) |
| 2 | 37 (22) |
| 3 | 41 (24) |
| 4 | 79 (46) |
| DIPSS components, no. (%) | |
| Age > 65 y | 9 (5) |
| Constitutional symptoms | 79 (47) |
| Hemoglobin < 10 g/dL | 120 (71) |
| Leukocyte count > 25 × 109/L | 50 (29) |
| Circulating peripheral blasts ≥ 1% | 95 (56) |
| DIPSS score, no. (%) | |
| Low | 21 (12) |
| Intermediate-1 | 48 (28) |
| Intermediate-2 | 50 (30) |
| High | 51 (30) |
| Characteristic . | Value . |
|---|---|
| No. of patients | 170 |
| Age range, y (median) | 12.1-78.9 (51.5) |
| Sex, male/female, no. (%) of patients | 93 (55)/77 (45) |
| Months from diagnosis to HCT, range (median) | 2-314 (15) |
| HCT-CI, no. (%) | 114 |
| 0 | 40 (35) |
| 1 | 19 (17) |
| 2 | 21 (19) |
| 3 | 14 (12) |
| 4 | 10 (9) |
| 5 | 5 (4) |
| 6 | 5 (4) |
| Type of myelofibrosis, no. (%) | |
| Primary | 101 (59) |
| Secondary | 69 (41) |
| Essential thrombocythemia | 46 (67) |
| Polycythemia vera | 22 (32) |
| Hairy cell leukemia | 1 (1) |
| Cytogenetic classification, no. (%) | |
| Favorable | 17 (10) |
| Normal | 88 (52) |
| Other | 37 (22) |
| Unfavorable | 25 (15) |
| Unknown | 3 (1) |
| JAK2 mutational status, no. (%) | |
| JAK2 wild-type | 51 (30) |
| JAK2-V617F mutant | 43 (25) |
| Not done | 76 (45) |
| Splenectomy, no. (%) | |
| No | 136 (80) |
| Yes | 31 (18) |
| Unknown* | 3 (2) |
| Grade of bone marrow fibrosis,20 no. (%) | |
| 1 | 13 (8) |
| 2 | 37 (22) |
| 3 | 41 (24) |
| 4 | 79 (46) |
| DIPSS components, no. (%) | |
| Age > 65 y | 9 (5) |
| Constitutional symptoms | 79 (47) |
| Hemoglobin < 10 g/dL | 120 (71) |
| Leukocyte count > 25 × 109/L | 50 (29) |
| Circulating peripheral blasts ≥ 1% | 95 (56) |
| DIPSS score, no. (%) | |
| Low | 21 (12) |
| Intermediate-1 | 48 (28) |
| Intermediate-2 | 50 (30) |
| High | 51 (30) |
A reliable spleen examination could not be performed in 3 patients because of body habitus.